Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition.
Oncolytic virus
adenovirus
checkpoint inhibitors
immunotherapy
tumor microenvironment
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
22 05 2020
22 05 2020
Historique:
entrez:
14
9
2020
pubmed:
15
9
2020
medline:
15
9
2020
Statut:
epublish
Résumé
Checkpoint inhibitors have revolutionized cancer therapy and validated immunotherapy as an approach. Unfortunately, responses are seen in a minority of patients. Our objective is to use engineered adenoviruses designed to increase lymphocyte trafficking and cytokine production at the tumor, to assess if they increase the response rate to checkpoint inhibition, as these features have been regarded as predictive for the responses. When Ad5/3-E2F-d24-hTNFa-IRES-hIL2 (an oncolytic adenovirus coding for TNFa and IL-2, also known as TILT-123) and checkpoint inhibitors were used together in fresh urological tumor histocultures, a significant shift toward immune activity (not only tumor necrosis alpha and interleukin-2 but also interferon gamma and granzyme B) and increased T-cell trafficking signals (CXCL10) was observed.
Identifiants
pubmed: 32923123
doi: 10.1080/2162402X.2020.1761229
pii: 1761229
pmc: PMC7458667
doi:
Substances chimiques
B7-H1 Antigen
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
1761229Informations de copyright
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
Références
Oncoimmunology. 2015 Aug 12;5(2):e1074377
pubmed: 27057442
Virus Res. 1989 Dec;14(4):339-46
pubmed: 2560294
Clin Cancer Res. 2014 Oct 1;20(19):5064-74
pubmed: 24714771
JCI Insight. 2018 Apr 5;3(7):
pubmed: 29618658
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Nat Rev Clin Oncol. 2017 Nov;14(11):655-668
pubmed: 28653677
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Mol Ther. 2018 Sep 5;26(9):2243-2254
pubmed: 30017877
Oncoimmunology. 2016 Feb 18;5(5):e1136046
pubmed: 27467954
J Immunother Cancer. 2020 Jan;8(1):
pubmed: 31940588
Nat Commun. 2017 Sep 19;8(1):592
pubmed: 28928380
Clin Dev Immunol. 2010;2010:284581
pubmed: 21253521
Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):E10119-E10126
pubmed: 30297397
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Mol Ther Oncolytics. 2016 Dec 31;4:77-86
pubmed: 28345026
Int J Cancer. 2017 Oct 1;141(7):1458-1468
pubmed: 28614908
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Lancet. 2019 Jun 15;393(10189):2404-2415
pubmed: 31079938
Mol Ther. 2016 Aug;24(8):1435-43
pubmed: 27357626
Expert Opin Biol Ther. 2016;16(3):397-406
pubmed: 26800463
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
Br J Cancer. 2016 Aug 23;115(5):553-63
pubmed: 27490802
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
J Clin Invest. 2018 Apr 2;128(4):1413-1428
pubmed: 29504948
PLoS One. 2018 Jun 6;13(6):e0196464
pubmed: 29874226
Clin Cancer Res. 2010 Aug 1;16(15):4046-56
pubmed: 20562209
Lancet. 2016 Apr 30;387(10030):1837-46
pubmed: 26970723
Cancer Immunol Res. 2015 May;3(5):449-54
pubmed: 25691326
Oncoimmunology. 2018 Apr 9;7(5):e1412902
pubmed: 29721366
Mol Ther. 2017 May 3;25(5):1107-1116
pubmed: 28392162
Contemp Oncol (Pozn). 2018 Mar;22(1A):61-67
pubmed: 29628796
Cancer Cell. 2015 Sep 14;28(3):285-95
pubmed: 26373277
Oncoimmunology. 2018 Aug 27;7(12):e1503032
pubmed: 30524901
Cell. 2017 Sep 7;170(6):1109-1119.e10
pubmed: 28886381
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
Oncolytic Virother. 2018 Jul 31;7:65-77
pubmed: 30105219
PLoS One. 2015 Jun 24;10(6):e0131242
pubmed: 26107883
Cancers (Basel). 2020 Jan 13;12(1):
pubmed: 31940998
Oncologist. 2017 Mar;22(3):311-317
pubmed: 28232599
Nat Rev Immunol. 2018 Aug;18(8):498-513
pubmed: 29743717
Cancer Sci. 2016 Oct;107(10):1373-1379
pubmed: 27486853
Nat Med. 2018 Jun;24(6):749-757
pubmed: 29867230